The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes.
暂无分享,去创建一个
Yuichi Sugiyama | Motohiro Kato | Koji Chiba | Y. Sugiyama | Motohiro Kato | Masato Horikawa | M. Horikawa | K. Chiba | M. Kato | Masato Horikawa | Motohiro Kato
[1] J. Domergue,et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. , 1994, The Journal of pharmacology and experimental therapeutics.
[2] I. Roots,et al. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test , 1994, Clinical pharmacology and therapeutics.
[3] P. Neuvonen,et al. Rifampin drastically reduces plasma concentrations and effects of oral midazolam , 1996, Clinical pharmacology and therapeutics.
[4] P. Maurel,et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. , 1990, Gastroenterology.
[5] R Ohlsson,et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[6] L. Lesko,et al. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[7] P. Neuvonen,et al. Rifampin reduces plasma concentrations and effects of zolpidem , 1997, Clinical pharmacology and therapeutics.
[8] U. Mansmann,et al. Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment. , 1997, International journal of clinical pharmacology and therapeutics.
[9] R. Bergstrand,et al. Omeprazole treatment does not affect the metabolism of caffeine. , 1991, Gastroenterology.
[10] H. Kusuhara,et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. , 2003, Drug metabolism and pharmacokinetics.
[11] R. Fisher,et al. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[12] G. Yee,et al. Pharmacokinetic Drug Interactions with Cyclosporin (Part I) , 1990, Clinical pharmacokinetics.
[13] Sean Kim,et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[14] S. Wrighton,et al. The use of human hepatocyte cultures to study the induction of cytochrome P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[15] L. Moore,et al. Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.
[16] A. Li,et al. Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes. , 1997, Chemico-biological interactions.
[17] P. Neuvonen,et al. The effect of dexamethasone on the pharmacokinetics of triazolam. , 1998, Pharmacology & toxicology.
[18] G. Kaatz,et al. Enzyme induction by phenobarbitone and vitamin K1 disposition in man. , 1984, British journal of clinical pharmacology.
[19] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[20] P. Maurel,et al. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. , 1996, Biochemical pharmacology.
[21] J. Miners,et al. Verapamil disposition--effects of sulphinpyrazone and cimetidine. , 1985, British journal of clinical pharmacology.
[22] E. Perucca,et al. Effect of low‐dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects [letter] , 1981 .
[23] J. Brockmöller,et al. Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C‐[N‐3‐methyl]‐caffeine breath test in poor and extensive metabolizers of S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.
[24] C. Bonfils,et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.
[25] G. Yee,et al. Pharmacokinetic Drug Interactions with Cyclosporin (Part II) , 1990, Clinical pharmacokinetics.
[26] A. Li,et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. , 1997, Chemico-biological interactions.
[27] A. Li,et al. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. , 1998, Chemico-biological interactions.
[28] U. Hofmann,et al. Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone , 2000, Clinical pharmacology and therapeutics.
[29] I. Roots,et al. Specific and dose‐dependent enzyme induction by omeprazole in human beings , 1994, Hepatology.
[30] L. Benet,et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole , 1997, Clinical pharmacology and therapeutics.
[31] S. Carruthers,et al. Quinidine-rifampin interaction. , 1981, The New England journal of medicine.
[32] D. Greenblatt,et al. In vitro approaches to predicting drug interactions in vivo. , 1998, Biochemical pharmacology.
[33] D. Waxman,et al. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. , 1999, Archives of biochemistry and biophysics.
[34] J. S. Sidhu,et al. Effects of chemical inducers on human microsomal epoxide hydrolase in primary hepatocyte cultures. , 1998, Biochemical pharmacology.
[35] J. Lehmann,et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.
[36] T. Tomson,et al. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. , 2003, British journal of clinical pharmacology.
[37] A. Li,et al. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. , 1995, The Journal of pharmacology and experimental therapeutics.
[38] M. Fromm,et al. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[39] S. J. Kovacs,et al. Morning Spot and 24‐Hour Urinary 6β‐Hydroxycortisol to Cortisol Ratios: Intraindividual Variability and Correlation under Basal Conditions and Conditions of CYP 3A4 Induction , 1999, Journal of clinical pharmacology.
[40] T. Izumi,et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. , 1996, The Journal of pharmacology and experimental therapeutics.
[41] E. Perucca,et al. Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects. , 1981, British journal of clinical pharmacology.
[42] S. Adams,et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S‐mephenytoin , 1997, Clinical pharmacology and therapeutics.
[43] Y. Sugiyama,et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.
[44] P. Maurel,et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[45] M. Rowland,et al. Cyclosporin-phenytoin interaction: re-evaluation using metabolite data. , 1987, British journal of clinical pharmacology.
[46] M Rowland,et al. Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.
[47] S. Wrighton,et al. Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. , 1998, Archives of biochemistry and biophysics.
[48] B. K. Park,et al. Measurement of urinary 6-β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin , 1979, European Journal of Clinical Pharmacology.
[49] P. Neuvonen,et al. Triazolam is ineffective in patients taking rifampin , 1997, Clinical pharmacology and therapeutics.
[50] T Nakagawa,et al. A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.
[51] C. Loi,et al. Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol. , 1998, Journal of clinical pharmacology.